Related Experiment Video

Updated: Jun 18, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Successful eradication of acquired factor-VIII-inhibitor using single low-dose rituximab

Martin Wermke, Malte von Bonin, Siegmund Gehrisch

    Haematologica
    |November 12, 2009
    PubMed
    Abstract

    No abstract available in PubMed .

    Related Experiment Videos

    Last Updated: Jun 18, 2026

    Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
    09:54

    Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

    Published on: May 22, 2020

    Related Concept Videos

    Venous Thrombosis III: Interprofessional Care01:29

    Venous Thrombosis III: Interprofessional Care

    Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
    Respiratory Syncytial Virus Disease01:29

    Respiratory Syncytial Virus Disease

    Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...

    Articles linked to this work by shared authors, journal, and citation graph.

    PRDM16 expression is an independent prognostic factor in AML with the double-mutant NPM1/FLT3-ITD genotype.

    Annals of hematology·2026

    Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.

    American journal of hematology·2026

    Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

    Blood·2025

    Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.

    American journal of hematology·2025

    Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

    Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.

    Blood·2025

    The use of MYD88 and IGH polymerase chain reaction in the diagnosis and follow-up of Bing-Neel syndrome.

    Haematologica·2026

    CD19 antigen: from tumor target to safety switch in CAR-T cell therapy.

    Haematologica·2026

    Adult-onset activated PI3Kδ syndrome presenting with HLH-like hyperinflammation, autoimmunity, and thrombosis: an underrecognized inborn error of immunity.

    Haematologica·2026

    Divergent roles of interleukin-12p40 and interleukin-18 in severe fibrosing chronic graft-versus-host-disease, immunity, and post-transplant outcomes.

    Haematologica·2026

    Response to comment on: "Ligature-induced periodontitis promotes Dnmt3aR878H-driven clonal hematopoiesis".

    Haematologica·2026

    Optimizing exposure: the case for dose-dense CAR T-cell administration.

    Haematologica·2026

    [Sarcoidosis from an immunological perspective - experience-based diagnosis and treatment with targeted therapies].

    Therapeutische Umschau. Revue therapeutique·2026

    [Immune-related adverse events of immune checkpoint inhibitors].

    Therapeutische Umschau. Revue therapeutique·2026

    Therapeutic drug monitoring of adalimumab for dose optimization during maintenance therapy in patients with ulcerative colitis: real-world data.

    Folia medica·2026

    Correction: A robust and scalable immunoadsorbent platform based on the high-affinity M03-IgG antibody for targeted IL-6 Removal in cytokine storm.

    Frontiers in immunology·2026

    Expanded dendritic cells loaded with placental gp96 to generate antigen-specific T cells for anti-tumor immunity: an in vitro study.

    Central-European journal of immunology·2026

    Protein Posttranslational Modifications in Immunity: Molecular Mechanisms and Therapeutic Targets.

    MedComm·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us